The QuicDNA project involves cross-sector partners and funders to ensure the widespread reach and impact of liquid biopsy technology. A liquid biopsy is a simple and non-invasive alternative to surgical tumour biopsies done through a blood test, or can be used to complement tumour biopsy to shorten the time to treatment. The video also features insights from Craig Maxwell, discussing the impact of this project, and the importance of ongoing fundraising efforts.
“I think Craig has been absolutely quite unique in this. He’s taken the opportunity, albeit with an advanced diagnosis of cancer, to say what can he do to improve both the system and improve outcomes for patients coming after him. Which is quite inspirational for the rest of us. He’s inspiring us to work more effectively across Wales.” Professor Tom Crosby, Cancer Clinical Director for Wales
Cancer can prevent people from living healthier and longer lives, and increase pressures on the health and social care system. We can help improve this by driving life science innovation to the frontline of care.
"Cancer care in Wales is advancing, but challenges remain. By showcasing innovations like QuicDNA and CanSense, we aim to inspire and show how innovative technologies can transform cancer detection and treatment. Partnerships across health, social care, and industry are vital. We foster collaboration to accelerate the deployment of innovative cancer care solutions.” - Cari-Anne Quinn, CEO, Life Sciences Hub Wales
